Amphastar Pharmaceuticals, Inc. Revenue 2012–2025
Amphastar Pharmaceuticals, Inc. reported $719.89M of revenue for fiscal 2025. That was 1.7% lower than fiscal 2024. Compared with fiscal 2020, the change was +105.8%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $719.89M | -1.7% |
| FY 2024 | $731.97M | +13.6% |
| FY 2023 | $644.39M | +29.1% |
| FY 2022 | $498.99M | +14.0% |
| FY 2021 | $437.77M | +25.1% |
| FY 2020 | $349.85M | +8.5% |
| FY 2019 | $322.36M | +9.4% |
| FY 2018 | $294.67M | +22.7% |
| FY 2017 | $240.18M | -5.9% |
| FY 2016 | $255.16M | +1.4% |
| FY 2015 | $251.52M | +19.5% |
| FY 2014 | $210.46M | -8.4% |
| FY 2013 | $229.68M | +12.4% |
| FY 2012 | $204.32M | — |
Source: Amphastar Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open AMPH 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Amphastar Pharmaceuticals, Inc. reported $719.89M of revenue for fiscal 2025. That was 1.7% lower than fiscal 2024. Compared with fiscal 2020, the change was +105.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Amphastar Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmphastar Pharmaceuticals, Inc. — frequently asked questions
What is Amphastar Pharmaceuticals, Inc.'s revenue?
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.89M for fiscal year 2025, per its SEC filings.
How has Amphastar Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2012 and 2025, AMPH's revenue grew at roughly 10.2% per year (compound annual rate), from $204.32M to $719.89M.
Where does this data come from?
Figures are computed from Amphastar Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.